Quick answer: Women do not need a universal “complete panel.” Start with current breast and cervical screening eligibility, history, symptoms, pregnancy plans, medicines and individual risks. Breast MRI, pelvic ultrasound or MRI, CA-125, DEXA, hormone tests, CAC and other imaging should be added only for a defined reason—not bundled automatically for every woman.
This page provides general education. It does not diagnose disease, choose a screening schedule for an individual reader or replace timely evaluation of symptoms such as a new breast lump, abnormal bleeding, severe pelvic pain, chest pain or sudden neurological symptoms.
Current Taiwan screening starting points
Taiwan's Health Promotion Administration currently provides mammography every two years for women aged 40–74. Cervical cytology is subsidised every three years for women aged 25–29; for women aged 30 and older it is subsidised annually, with screening recommended at least every three years. Eligibility and clinical advice can change, so confirm the current rules at the time of care.
Screening is not diagnosis. An abnormal result requires appropriate diagnostic follow-up, and a normal result cannot guarantee that cancer is absent or will not develop later.
Breast imaging: one test does not fit everyone
| Test |
Role |
Key limit |
| Mammography / DBT |
Primary screening imaging for eligible women. |
Uses low-dose X-rays and may be less sensitive in dense tissue; a result must be interpreted with the full clinical context. |
| Breast MRI |
Additional screening for selected high-risk women, generally together with mammography. |
It is not a replacement for mammography, often uses gadolinium contrast and produces more false-positive findings. |
| Breast ultrasound |
Targeted evaluation or selected supplemental use. |
It is not a universal replacement for mammography and can also lead to false-positive findings. |
ACS recommends MRI plus mammography for women at high risk, including certain women with a lifetime risk around 20%–25% or greater based mainly on family-history models. ACS recommends against MRI screening when lifetime risk is below 15% and states that evidence is insufficient for some intermediate-risk groups, including dense breasts alone. A clinician should calculate risk and select the protocol.
Cervical screening and HPV
HPV vaccination reduces risk but does not remove the need for cervical screening under current guidance. The appropriate test and interval depend on age, prior results, treatment history, immune status and whether the cervix is present. Symptoms or an abnormal result require diagnostic care rather than simply repeating a routine screen.
Ovarian cancer, CA-125 and pelvic ultrasound
USPSTF recommends against ovarian-cancer screening in asymptomatic women who are not known to have a high-risk hereditary cancer syndrome. CA-125 and transvaginal ultrasound can produce false-positive results and unnecessary surgery. A strong family history or known pathogenic variant should prompt genetics and specialist assessment; it does not create a universal six-month protocol from this article.
Pelvic ultrasound or MRI may be appropriate for symptoms or a finding that needs clarification. Neither is a broad screen that reliably excludes ovarian, uterine or other pelvic cancer. The imaging and any need for biopsy are selected by the responsible clinician.
Bone-density screening
Current USPSTF guidance recommends osteoporosis screening for women aged 65 or older and for postmenopausal women under 65 who are at increased fracture risk after clinical risk assessment. This article does not recommend routine premenopausal baseline DEXA or a fixed repeat interval. Body-composition tracking is a different use and does not itself establish a medical need for repeat scans.
Hormone and fertility tests
There is no universal “full hormone panel” for reproductive age, perimenopause or post-menopause. Tests are selected to answer a specific question. AMH can contribute to assessment of ovarian reserve in an appropriate fertility evaluation, but a single value does not directly measure egg quality, guarantee natural conception or predict the exact age of menopause. Results should be interpreted with age, history and other clinical information.
Cardiovascular testing
Women should receive standard cardiovascular risk assessment, including blood pressure, smoking, diabetes and lipid factors. An ECG, CAC scan, echocardiogram or CCTA is not automatically required because of sex or menopause. A clinician may use selected tests when symptoms or a risk decision justify them.
Safety and operational confirmation
- Tell the facility about pregnancy or possible pregnancy, breastfeeding, kidney disease, allergies, implants and prior reactions before imaging.
- Do not stop, start or change medicines or hormones based on this article.
- Confirm the exact imaging protocol, contrast plan, facility, report language, DICOM delivery, turnaround and follow-up in writing.
- Confirm price, currency, inclusions, exclusions, pathology charges and cancellation terms in the live catalogue or written quotation.
Primary references
Blog
